[go: up one dir, main page]

BR0202204A - Formulações estabilizadas - Google Patents

Formulações estabilizadas

Info

Publication number
BR0202204A
BR0202204A BR0202204-4A BR0202204A BR0202204A BR 0202204 A BR0202204 A BR 0202204A BR 0202204 A BR0202204 A BR 0202204A BR 0202204 A BR0202204 A BR 0202204A
Authority
BR
Brazil
Prior art keywords
stabilized formulations
stabilized
formulations
stabilizing
ways
Prior art date
Application number
BR0202204-4A
Other languages
English (en)
Inventor
Anne Billotte
Sharon Pavitt
Alan John Pettman
Zena Elizabethflorence Smith
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9916729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0202204(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of BR0202204A publication Critical patent/BR0202204A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

"FORMULAçõES ESTABILIZADAS". A presente invenção relaciona-se com maneiras de estabilizar o maleato de anlodipina para evitar a formação do produto de adição de Michael indesejado e com as composições farmacêuticas estabilizadas obtidas a partir daquele.
BR0202204-4A 2001-06-15 2002-06-12 Formulações estabilizadas BR0202204A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0114709.9A GB0114709D0 (en) 2001-06-15 2001-06-15 Stabilised formulations of amlodipine maleate

Publications (1)

Publication Number Publication Date
BR0202204A true BR0202204A (pt) 2003-04-01

Family

ID=9916729

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0202204-4A BR0202204A (pt) 2001-06-15 2002-06-12 Formulações estabilizadas

Country Status (6)

Country Link
EP (1) EP1266654A1 (pt)
JP (1) JP2003040775A (pt)
BR (1) BR0202204A (pt)
CA (1) CA2390636C (pt)
GB (1) GB0114709D0 (pt)
MX (1) MXPA02005961A (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03005886A (es) 2000-12-29 2005-04-19 Pfizer Ltd Derivado de aspartato de amlodipina como antagonista del canal de calcio.
US6653481B2 (en) 2000-12-29 2003-11-25 Synthon Bv Process for making amlodipine
MXPA03005882A (es) 2000-12-29 2005-04-19 Pfizer Ltd Derivado amida de amlodipina.
WO2002053541A1 (en) 2000-12-29 2002-07-11 Pfizer Limited Amide derivative of amlodipine
WO2003089414A1 (en) * 2002-04-13 2003-10-30 Hanlim Pharmaceutical Co., Ltd. Amlodipine nicotinate and process for the preparation thereof
DK1435239T3 (da) * 2002-12-31 2006-07-31 Cimex Pharma Ag Stabiliseret og let forarbejdeligt granulat af amlodipin--maleat
CA2559670A1 (en) * 2003-04-14 2004-10-28 Gabor Pragai Stable amlodipine maleate formulations
AU2004289252C1 (en) 2003-11-08 2013-06-20 Prothera Biologics, Inc. Preparation and composition of Inter-alpha inhibitor proteins from human plasma for therapeutic use
KR100825039B1 (ko) 2005-01-21 2008-04-24 대원제약주식회사 안정성이 개선된 암로디핀 말레이트염 정제
PT2291654T (pt) 2008-05-28 2018-06-15 Prothera Biologics Inc Preparação e composição de proteínas inibidoras de interalfa do sangue
AU2013312215C1 (en) 2012-09-09 2018-09-06 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
CN109789193A (zh) 2016-09-13 2019-05-21 普罗瑟拉生物公司 使用间α抑制蛋白治疗肺病的方法
EP3615937B1 (en) 2017-04-25 2026-01-28 Prothera Biologics, Inc. Methods for quantifying inter-alpha inhibitor proteins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03005885A (es) * 2000-12-29 2005-04-19 Pfizer Ltd Procedimiento para fabricar maleato de amlodipina.
AT5874U1 (de) * 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
EP1346214A2 (en) * 2000-12-29 2003-09-24 Pfizer Limited Reference standards and processes for determining the purity or stability of amlodipine maleate

Also Published As

Publication number Publication date
GB0114709D0 (en) 2001-08-08
CA2390636C (en) 2005-05-03
JP2003040775A (ja) 2003-02-13
EP1266654A1 (en) 2002-12-18
CA2390636A1 (en) 2002-12-15
MXPA02005961A (es) 2003-01-07

Similar Documents

Publication Publication Date Title
TR200101499T1 (tr) Azepinoindol türevleri, hazırlanmaları ve kullanımları.
MY138252A (en) Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
BR9916835A (pt) Composição de galantamina de liberação controlada
PT1235799E (pt) Forma polimorfica de atorvastatina-calcio
WO2003053359A3 (en) 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
GB0129260D0 (en) Pharmaceutical compositions and their uses
BR0202204A (pt) Formulações estabilizadas
TW200628447A (en) Triamide-substituted heterobicyclic compounds
TNSN04165A1 (en) Substituted hydroxyethylamines
ATE486587T1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
TNSN04034A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
WO2001080873A3 (en) Thrombopoietin receptor modulating peptide
BR0311327A (pt) Composição farmacêutica contendo oxcarbazepina com liberação sustentada de um ingrediente ativo
EP2157083A3 (en) Pharmaceutical compositions containing crystalline form (I) of lercanidipine hydrochloride
WO2002011666A3 (en) Derivatives of branched-chain lipophilic molecules and uses thereof
MXPA04002282A (es) Nuevos compuestos y preparaciones como inhibidores de la catepsina.
WO2002060435A8 (fr) Cryptotanshinone permettant de prevenir et d'attenuer la maladie d'alzheimer
DE59909607D1 (de) Tan-1057 derivate
MXPA03008801A (es) Aril oxima-piperazinas utiles como antagonistas de ccr5.
IL171992A0 (en) Storage-stable fluorescent whitener formulations
MXPA03011128A (es) Composicion de sabor y fragancia.
WO2002056840A3 (de) Kosmetisches und/oder pharmazeutisches mittel acylierte aminosaüre enthaltend.
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
EP1446400A4 (en) Piperidin derivatives, process for their preparation and pharmaceutical composition for the treatment of Alzheimer's disease containing these derivatives
FR2857026B1 (fr) Produit immunomodulateur obtenu a partir d'une culture de bifidobacterium et compositions le contenant

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADE(S).

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2055 DE 25/05/2010.